Methotrexate is a frequently used chemotherapy drug. Here, David Sabatini and colleagues describe a metabolic feature that modulates the response of cancer cells to methotrexate: they show that altered histidine metabolism is a determinant of methotrexate sensitivity. In a mouse model of leukaemia, supplementation with histidine enhances the response to the drug. This work suggests that histidine supplementation could be used in the clinic to improve the efficacy of methotrexate.
- Histidine metabolism boosts cancer therapy (News & Views p484, doi: 10.1038/d41586-018-05573-4)
- Histidine catabolism is a major determinant of methotrexate sensitivity (Letter p632, doi: 10.1038/s41586-018-0316-7)
Recent Hot Topics
- Aug 16Reducing yeast chromosome numbers has only minor effect on cell fitness
- Aug 9Xenon isotopes reveal history of volatile recycling into the mantle
- Aug 2Succinate goes in to BAT, turning up the heat on metabolic disease
- Jul 26Histidine metabolism determines sensitivity to methotrexate
- Jul 19Vein-to-artery cell fate switching examined
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.